Skip to main content

REGULACION DE MECANISMOS CELULARES AUTONOMOS Y NO AUTONOMOS POR NUEVAS INTERACCIONES SINTETICO-LETALES CON KRAS: IMPLICACION FUNCIONAL, MOLECULAR Y CLINICA EN CANCER DE PULMON

SAF2017-89944-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

  • Macaya, Irati
  • Roman, Marta
  • Welch, Connor
  • Entrialgo-Cadierno, Rodrigo
  • Salmón, Marina
  • Santos, Alba
  • Feliu, Iker
  • Kovalski, Joanna
  • López, Inés
  • Rodríguez-Remirez, María
  • Palomino-Echeverria, Sara
  • Lonfgren, Shane M.
  • Ferrero, Macarena
  • Calabuig, Silvia
  • Ludwig, Iziar A.
  • Lara-Astiaso, David
  • Jantus-Lewintre, Eloisa
  • Guruceaga, Elizabeth
  • Narayanan, Shruthi
  • Ponz-Sarvise, Mariano
  • Pineda-Lucena, Antonio
  • Lecanda, Fernando
  • Ruggero, Davide
  • Khatri, Purvesh
  • Santamaría, Enrique
  • Fernandez-Irigoyen, Joaquín
  • Ferrer, Irene
  • Paz-Ares, Luis
  • Drosten, Matthias
  • Barbacid, Mariano
  • Gil-Bazo, Ignacio
  • Vicent, Silve
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitumor effect is highly determined by compensatory mechanisms arising in defined cell types or tumor subgroups. A potential strategy to find drug combinations targeting a larger fraction of KRAS-mutated lung cancers may capitalize on the common, distal gene expression output elicited by oncogenic KRAS. By integrating a signature-driven drug repurposing approach with a pairwise pharmacological screen, here we show synergistic drug combinations consisting of multi-tyrosine kinase PKC inhibitors together with MEK1/2 or KRASG12C inhibitors. Such combinations elicit a cytotoxic response in both in vitro and in vivo models, which in part involves inhibition of the PKC inhibitor target AURKB. Proteome profiling links dysregulation of MYC expression to the effect of both PKC inhibitor-based drug combinations. Furthermore, MYC overexpression appears as a resistance mechanism to MEK1/2 and KRASG12C inhibitors. Our study provides a rational framework for selecting drugs entering combinatorial strategies and unveils MEK1/2- and KRASG12C-based therapies for lung cancer., M.R. was supported by a fellowship from MICIU (FPU15/00173), R.E. by a donation from Mauge Burgos de la Iglesia’s family. The Proteomics Platforms of Navarrabiomed led by E.S. and J.F.-I. is a member of Proteored, PRB3 and is supported by grant PT17/0019 of the PE I + D + i 2013–2016, funded by ISCIII and ERDF. E.J.-L. was supported by Foundation of Spanish Association Against Cancer (PROYE18012ROSE), by Centro de Investigación Biomédica en Red (CIBERONC; CB16-12-00350), and by Generalitat Valenciana (AICO/2021/333). F.L. was funded by the Gobierno de Navarra (Ref. 34/2021), the Cancer Research Thematic Network of the Instituto de Salud Carlos III (RTICC RD12/0036/0066), PID2021-122638OB-I00 MCIN/AEI/10.13039/501100011033/ FEDER, UE and by FEDER “Una manera de hacer Europa”. I.F. was funded by FIS PI19/00320 and by the Miguel Servet Program CP21/00052. S.V. was supported by Ministerio de Ciencia, Innovación y Universidades, Convocatoria 2019 para incentivar la Incorporación Estable de Doctores (IED2019-001007-I), by FEDER /Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación (SAF2017-89944-R and PID2020‐116344‐RB‐100/MCIN/AEI/10.13039/501100011033, by a Leonardo Grant for Researchers and Cultural Creators 2018 from BBVA Foundation, by a seed grant at the I Convocatoria Proyectos Prueba de Concepto from PRB3-Proteored (Institute of Health Carlos III-ISCIII), by Fundació La Marató de TV3 (474/C/2019), and by Foundation of Spanish Association Against Cancer - Strategic Projects 2020 (PROYE20029VICE). M.P.-S. and S.V. were also funded by Fundación Alberto Palatchi. None of the funding sources were involved in the decision to submit the article for publication., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

  • Macaya, Irati
  • Roman, Marta
  • Welch, Connor
  • Entrialgo-Cadierno, Rodrigo
  • Salmon, Marina
  • Santos, Alba
  • Feliu, Iker
  • Kovalski, Joanna
  • López Erdozain, Inés
  • Rodríguez-Remírez, María
  • Palomino Echeverría, Sara
  • Lonfgren, Shane M.
  • Ferrero, Macarena
  • Calabuig, Silvia
  • Ludwig, Iziar A.
  • Lara-Astiaso, David
  • Jantus-Lewintre, Eloisa
  • Guruceaga, Elizabeth
  • Narayanan, Shruthi
  • Ponz Sarvisé, Mariano
  • Pineda Lucena, Antonio
  • Lecanda, Fernando
  • Ruggero, Davide
  • Khatri, Purvesh
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Ferrer, Irene
  • Paz-Ares, Luis
  • Drosten, Matthias
  • Barbacid, Mariano
  • Gil-Bazo, Ignacio
  • Vicent, Silvestre
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitumor effect is highly determined by compensatory mechanisms arising in defined cell types or tumor subgroups. A potential strategy to find drug combinations targeting a larger fraction of KRAS-mutated lung cancers may capitalize on the common, distal gene expression output elicited by oncogenic KRAS. By integrating a signature-driven drug repurposing approach with a pairwise pharmacological screen, here we show synergistic drug combinations consisting of multi-tyrosine kinase PKC inhibitors together with MEK1/2 or KRASG12C inhibitors. Such combinations elicit a cytotoxic response in both in vitro and in vivo models, which in part involves inhibition of the PKC inhibitor target AURKB. Proteome profiling links dysregulation of MYC expression to the effect of both PKC inhibitor-based drug combinations. Furthermore, MYC overexpression appears as a resistance mechanism to MEK1/2 and KRASG12C inhibitors. Our study provides a rational framework for selecting drugs entering combinatorial strategies and unveils MEK1/2- and KRASG12C-based therapies for lung cancer., M.R. was supported by a fellowship from MICIU (FPU15/00173). The Proteomics Platforms of Navarrabiomed led by E.S. and J.F.-I. is a member of Proteored, PRB3 and is supported by grant PT17/0019 of the PE I + D + i 2013¿2016, funded by ISCIII and ERDF. E.J.-L. was supported by Foundation of Spanish Association Against Cancer (PROYE18012ROSE), by Centro de Investigación Biomédica en Red (CIBERONC; CB16-12-00350), and by Generalitat Valenciana (AICO/ 2021/333). F.L. was funded by the Gobierno de Navarra (Ref. 34/2021), the Cancer Research Thematic Network of the Instituto de Salud Carlos III (RTICC RD12/0036/0066), PID2021-122638OB-I00 MCIN/AEI/ 10.13039/501100011033/ FEDER, UE and by FEDER ¿Una manera de hacer Europa¿. I.F. was funded by FIS PI19/00320 and by the Miguel Servet Program CP21/00052. S.V. was supported by Ministerio de Ciencia, Innovación y Universidades, Convocatoria 2019 para incentivar la Incorporación Estable de Doctores (IED2019-001007-I), by FEDER /Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación (SAF2017-89944-R and PID2020¿116344¿RB¿100/MCIN/ AEI/10.13039/501100011033, by a Leonardo Grant for Researchers and Cultural Creators 2018 from BBVA Foundation, by a seed grant at the I Convocatoria Proyectos Prueba de Concepto from PRB3-Proteored (Institute of Health Carlos III-ISCIII), by Fundació La Marató de TV3 (474/ C/2019), and by Foundation of Spanish Association Against Cancer - Strategic Projects 2020 (PROYE20029VICE). M.P.-S. and S.V. were also funded by Fundación Alberto Palatchi.